Podcasts about biologics

Biology may be the most important technology we take off planet, and Mario Maggio is building the hardware to prove it. The founder and CEO of Ambrosia Space joins Erum Azeez Khan and Karl Schmieder to explain why space bioprocessing has been stuck at 10 to 20 milliliters while bench scientists on Earth work at 250 milliliters and beyond, and what changes when a two and a half liter fed batch bioreactor with pH, dissolved oxygen, and total cell density sensors finally flies. Mario traces his path from aerospace propulsion and the Nova C lunar lander at Intuitive Machines to life support systems at Paragon and Axiom Space, and the realization that biology is the best CO2 scrubber, oxygen source, and chemical factory available for long duration missions where petroleum, farms, and easy resupply do not exist. The conversation digs into the engineering reality of fluids and gas in microgravity, why glass and ceramics never fly, the stainless steel and aluminum builds that replace them, the intentional and unintentional bacteria that come with building a bioreactor from scratch, and the NASA TechLeap winning CellSep continuous flow centrifuge that carries cells and secreted products into downstream processing without gravity. Mario also lays out the near term commercial case, from protein crystallization and monoclonal antibodies that behave differently in orbit to biofuels, vitamin production, medicines, and the big silver tanks that will feed astronauts because there will be no farms or cattle. He offers a candid read on artificial gravity gradients, why the Moon matters for building large vehicles in space, and why the same hardware that grows yeast for beer on Mars becomes the root of better biomanufacturing on Earth. Erum and Karl open with field notes from Bio Innovations North America in Omaha, including Midwest feedstock advantage, consortia momentum, the 30 percent of cost hiding in downstream processing, and why Smucker and Mars are actively scouting biotech innovators.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and speak with the leaders and innovators using biology to change the world. Biology is the world's oldest technology, and it can be engineered. So, what are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) Why Biology Is the Best Commercial Case for Space(00:04:52) Bio Innovations North America and the Midwest Bioeconomy(00:07:21) Why Smucker and Mars Are Scouting Biotech Innovators(00:11:42) Inside Ambrosia Space: Bioreactors Built for Orbit(00:15:24) Scaling Past 150 Milliliters: Space Biology's Volume Problem(00:18:12) Stainless Steel, Leaks, and Why Glass Never Flies(00:21:36) NASA TechLeap and the CellSep Continuous Flow Centrifuge(00:26:08) Protein Crystals and Monoclonal Antibodies Made in Microgravity(00:31:22) Artificial Gravity, Lunar Bases, and Closing the Loop on Life Support(00:36:12) Quick Fire: Space Food Reality, HAL, and Biologics in OrbitLinks and Resources:Mario MaggioAmbrosia Space LinkedInAmbrosia Space111. Space Genes and Subway Scenes: Chris Mason on Planning Life's Next Big Leap93. Houston, We Have a Protocol: NASA's Kate Rubins on Biotech in Space187. One Small Step for a Microbe: Lynn Rothschild's Leap from Astrobiology to Bioengineering at NASA185. Brick Happens: Chris Maurer of Redhouse Studio Redesigns Remote Living for Earth and Mars152. Crystals in the Cosmos: Varda Rewrites Drug Formulation in MicrogravityGrow Everything LinkedInTopics Covered:space biomanufacturing, Ambrosia Space, orbital bioreactors, microgravity biotechnologyHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself to meet increasing global demand for affordable treatments. This initiative not only enhances their production capabilities but also aligns with the push from healthcare systems worldwide for more economical care options. The vertical integration model promises to streamline production, reduce supply chain issues, and maintain high-quality standards, reinforcing Sandoz's competitive position in the biosimilars market. Meanwhile, Amgen has achieved a noteworthy milestone with its drug Imdelltra (tarlatamab-dlle), which met its Phase 3 overall survival endpoint for extensive-stage small-cell lung cancer (SCLC) maintenance therapy. Imdelltra, a bispecific T-cell engager targeting DLL3, represents a novel approach in oncology, potentially setting a new standard of care for SCLC patients who have severely limited treatment options. The positive trial results could lead to regulatory approval, broadening access to this innovative therapy and potentially improving patient outcomes significantly. Regulatory stability is on the horizon with the FDA appointing permanent heads for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). This leadership continuity is crucial as it supports the agency's ongoing restructuring efforts aimed at enhancing efficiency and oversight. Stable leadership within these centers ensures rigorous drug evaluation processes continue, which is critical for timely approvals and has a direct impact on drug developers' strategic planning and market entry timelines. Clinical trials continue to yield varied results, showcasing the inherent uncertainties in drug development. AstraZeneca's Tozorakimab showed promise with approximately a 30% reduction in exacerbations in Phase 3 trials for chronic obstructive pulmonary disease (COPD), hinting at improved management of respiratory diseases through targeted monoclonal antibody therapies. Conversely, challenges persist as Evommune's Evo756 did not meet its Phase 2b trial expectations for atopic dermatitis, and Tyra Biosciences' Dabogratinib fell short in non-muscle invasive bladder cancer trials—highlighting the unpredictable nature of clinical research. Investment flows into biopharmaceuticals remain robust, with Encoded Therapeutics raising $275 million to advance its gene therapy program for Dravet syndrome. Similarly, Luma Group has secured $410 million for ventures focusing on ophthalmology and cellular rejuvenation technologies. Such investments reflect strong confidence in gene and cell therapies' transformative potential on patient care. On the mergers and acquisitions front, Sernova Biotherapeutics' merger with Seraxis to form Betanova Biotherapeutics exemplifies how companies are consolidating expertise to enhance R&D capabilities and expand their market reach, particularly in cell therapy solutions for diabetes management. These strategic consolidations indicate ongoing efforts to leverage synergies that could redefine therapeutic landscapes. The biopharmaceutical sector is also seeing shifts due to ongoing geopolitical tensions between the U.S. and China, pushing companies to seek investment opportunities outside China. This diversification strategy aims to mitigate geopolitical risks while continuing global innovation efforts. In obesity treatment research, partnerships like those between GemPharmaTech signal new frontiers beyond GLP-1 receptor agonists. These collaborations highlight an industry commitment to tackling global health challenges with innovative therapies that prioritize efficacy and safety. These developments collectively paint a picture of a dynamic industry marked by scientific breakthroughs, strategic investments, regulatory evolution, and significant challenges in clinical trials. As these sectors evolve, they promise exciting advancements that could profoundly redefine global healthcare paradigms. The focus remains on overcoming therapeutic barriers through sustained research efforts and innovative approaches—a testament to the industry's relentless pursuit of improving patient care outcomes worldwide.Support the show

Send us Fan MailWhat if the future of regenerative medicine isn't simply making the body grow more tissue - but teaching it exactly WHERE to grow it?That's the idea behind NELL-1, a naturally occurring protein being developed to promote controlled bone formation and potentially transform spinal fusion.Today we're exploring a fascinating area of regenerative medicine: can we make the body build new bone - but do it more precisely, more predictably, and with fewer of the complications associated with today's approaches?My guest is Jeffrey Frelick, President and CEO of Bone Biologics ( https://www.bonebiologics.com/ ), a clinical-stage medtech company developing a new approach to bone regeneration based on a proprietary recombinant protein called NELL-1.NELL-1 is particularly intriguing because it is an osteogenic growth factor that appears to act more selectively on cells involved in bone formation than traditional bone morphogenetic proteins such as BMP-2. Preclinical studies have demonstrated significant increases in bone formation and spinal fusion, including studies in large-animal models.Bone Biologics is now taking that science toward the clinic with its NB1 bone graft device combined with NELL-1, currently being evaluated in a first-in-human pilot clinical study.Jeffrey brings more than 25 years of experience across the medical-device and healthcare industries. Before becoming CEO of Bone Biologics in 2019, he served as the company's COO. Earlier in his career, he was a medical-technology equity research analyst at Canaccord Genuity, ThinkEquity and Lazard, following the industry from the Wall Street perspective. He also worked in strategic consulting at Boston Biomedical Consultants and began his career in diagnostics and medical technology, including roles at Becton Dickinson.Jeffrey holds a B.S. in Biology from the University of Pittsburgh and an MBA from Suffolk University's Sawyer Business School.Today we're going to talk about the science of NELL-1, the future of spinal fusion and bone grafting, why precision may be so important in regenerative medicine, and what it takes to move a promising bone-growth technology from the laboratory into actual patients.#BoneRegeneration #NELL1 #SpinalFusion #RegenerativeMedicine #Orthopedics #BoneHealth #MedicalInnovation #MedTech #Biotechnology #Biotech #StemCells #TissueEngineering #SpineSurgery #Orthobiologics #BoneBiologics #MedicalDevices #PrecisionMedicine #RegenerativeMedicine #HealthcareInnovation #FutureOfMedicine #Science #Technology #Innovation #ProgressPotentialAndPossibilities #PPPSupport the show

Drs. Chase and Griffiths discuss how to choose biologic therapies for allergic asthma using a personalized approach based on biomarkers, asthma severity, comorbid type 2 diseases, and practical factors (eg, dosing and access). They highlight the importance of reducing steroid use, educating patients about biologics, and continually reassessing treatment to improve control and quality of life.

Starting a biologic can feel intimidating, especially if you are worried it means being on medication forever, or wondering if it will actually replace your inhaler or your next sinus surgery. After this episode, we hope your biggest biologics questions are answered. Kortney and Dr. Payel Gupta are joined by Dr. Giselle Mosnaim, an allergist and immunologist, to walk through the united airway, what uncontrolled disease really means, and the most common questions patients have before starting a biologic. What we cover in this episode about biologics for asthma, COPD, and nasal polyps The united airway. Why the nose and lungs share the same lining, and why the same biologics can treat conditions in both. What a biologic actually is. How it targets one specific part of the immune system instead of suppressing the whole thing like steroids. What uncontrolled disease means. Why taking your medication as prescribed does not always mean your asthma, COPD, or nasal polyps are under control. The goal of starting a biologic. What results to expect, how biologics work alongside your inhaler or nasal spray instead of replacing it, and how they can reduce the need for repeat sinus surgery. Common myths and fears. Answers to real patient worries about weight gain, needles, side effects, pregnancy, and being on a biologic long term. ________ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute for professional medical advice. Always consult with your healthcare provider for any medical concerns.  

The Varginha Biologics, Skinwalker Ranch, more #News #UFO #Podcast   Attribution Space.com Evidence of controversial Planet 9 uncovered in sky surveys taken 23 years apart Link: https://www.space.com/astronomy/solar-system/evidence-of-controversial-planet-9-uncovered-in-sky-surveys-taken-23-years-apart   The Varginha Biologics with Leslie Kean via @InterstellarUAP Link: https://x.com/InterstellarUAP/status/2094590496538591575?s=20   Leslie Kean: "I spoke with Government insiders who confirmed The 1996 Varginha UFO Crash in Brazil was REAL" via @InterstellarUAP Link: https://x.com/InterstellarUAP/status/2095221469274075529?s=20   Skinwalker Ranch and Post Malone via @InterstellarUAP Link: https://x.com/InterstellarUAP/status/2094870883902919063?s=20 

(00:00:00) 231b: "I am Allergic to EVERYTHING: Really?" Docs Discuss Allergy Immunology (00:00:11) Welcome to Itchy and Bitchy (00:00:42) Doc Itchy Medical Pet Supplements (00:01:06) The Allergy Enigma (00:03:03) Genetic Predisposition to Allergies (00:05:49) The Complexities of Allergic Reactions (00:08:41) Immunological Mechanisms of Allergies (00:18:40) The Allergy Epidemic (00:23:48) Treatment Options for Allergies (00:31:12) Monoclonal Antibodies: A Breakthrough in Allergy Treatment (00:34:45) The Final Frontier: Steroids and Other Powerful Medications Your immune system is a bouncer with a hair trigger. This episode breaks down the actual allergy cascade, T helper cells barking orders, mast cells detonating, histamine flooding the scene — and why your dog's itchy, oozy ears run on the exact same wiring. Then we get to the good stuff: monoclonal antibodies (Mabs), the designer proteins quietly rewriting allergy medicine. Cytopoint muzzles IL-31 so your dog stops shredding the couch; Dupixent blocks IL-4 and IL-13 so humans stop shredding their own skin. Same playbook, different species. Finally, the patient who's "allergic to literally everything", every antibiotic, every dye, every vitamin. Spoiler: the research points less to true allergy and more to anxiety, somatization, and the nocebo effect. Legit reaction or brain doing a bit? We referee.Get the receipts and the reading list at itchyandbitchy.com.Become a supporter of this podcast: https://www.spreaker.com/podcast/itchy-and-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

This week, Andy and Pavel examine some of the biggest claims in the UFO world. From Eric Davis's revelations on the podcast and Tim Gallaudet's possible Atlantis discovery, to Lazar's nine recovered craft, Grusch suggesting the real number could be between 25 and 100, and more whistleblowers preparing to speak out. How watertight are these extraordinary claims, and where is the evidence?https://www.youtube.com/@psicoactivopodcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest strategic moves, regulatory updates, and scientific breakthroughs shaping these dynamic industries. Roche is making headlines with its substantial $750 million investment to expand its Genentech facility in Oregon. This expansion is set to double the plant's capacity by 2031, focusing particularly on enhancing its fill-finish manufacturing capabilities. The fill-finish process is integral to drug production, involving the sterilization and filling of drug products into containers for distribution. This move not only underscores Roche's commitment to strengthening its manufacturing infrastructure but also highlights its strategic foresight in bolstering supply chain resilience. By increasing the production of biologics—key players in oncology, immunology, and neurology—Roche is positioning itself to meet growing global demand and potentially accelerate the delivery of critical medications. In other strategic developments, Ambros Therapeutics and Werewolf Therapeutics have decided to join forces in a $150 million merger. This move focuses on developing treatments for Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare pain disorder. The merger signifies a concerted effort to address niche therapeutic areas by pooling resources and expertise in small molecule development. Such alliances are crucial for innovating treatments for conditions that have historically faced unmet medical needs, paving the way for more targeted therapeutic interventions. Aurinia Pharmaceuticals has reached a significant milestone by settling a patent litigation case with Teva Pharmaceuticals. This settlement secures market exclusivity for Aurinia's drug Lupkynis until December 2036. Lupkynis is used in treating autoimmune conditions, and maintaining this exclusivity gives Aurinia a competitive edge by delaying generic competition. It highlights the importance of robust patent protection strategies in sustaining market share and fostering continued investment in drug innovation. On the regulatory front, the FDA has published 55 product-specific guidances aimed at streamlining generic drug development and accelerating ANDA approvals. These guidances play a pivotal role in enhancing the regulatory framework surrounding generic drug manufacturing, especially within oncology. By providing clearer pathways for approval, the FDA facilitates increased competition and potentially reduces drug costs, impacting patient accessibility and healthcare expenditure positively. However, not all news is favorable. Boehringer Ingelheim has voluntarily put on hold its Phase 1 trial of BI 3031185 due to a safety event involving a small molecule oral drug targeting neurological disorders such as borderline personality disorder and ADHD. Safety holds like this one underline the inherent challenges and risks involved in drug development, emphasizing the critical nature of rigorous safety assessments. Furthermore, political pressures are mounting on the FDA as lawmakers urge caution regarding clinical data from China following deaths in gene therapy trials. This situation underscores ongoing concerns about patient safety and data integrity in global clinical trials, which could have significant implications for international collaborations and regulatory policies. In a regulatory setback, Xspray Pharma received a complete response letter from the FDA for Dasynoc (dasatinib), intended for treating chronic myeloid leukemia and acute lymphoblastic leukemia. Such challenges highlight the complexities of securing approvals for oncology drugs where manufacturing issues can impede progress. Xspray Pharma faced another setback as its approval bid for Dasynoc was rejected again due to ongoing manufacturing concerns—underscoring regulatory scrutiny aimed at ensuring drug safety and efficacy standards are met. Turning our attention to neuroscience innovation, Lundbeck is actively evolving its focus under CEO Charl van Zyl's leadership. Nearly three years into his tenure, van Zyl is steering Lundbeck towards becoming a formidable "neuroscience challenger." This strategy underscores the company's commitment to innovation within the field of neuroscience, potentially leading to new therapeutic discoveries and treatments for neurological disorders. Meanwhile, Novo Nordisk's oral GLP-1 receptor agonist Wegovy is regaining traction as Eli Lilly's rival product experiences delays. This resurgence highlights Wegovy's potential impact within the competitive landscape of oral weight-loss solutions aimed at tackling obesity—a condition affecting millions globally. In Europe, Johnson & Johnson secured EU approval for Tecvayli-Darzalex Combo—a milestone that expands treatment options for multiple myeloma patients through combination therapies. In summary, these developments reflect a landscape marked by significant investments in manufacturing capabilities, strategic mergers targeting rare diseases, robust patent strategies protecting market exclusivity, and regulatory efforts to expedite generic drug approvals. Ongoing challenges within clinical trials emphasize safety and efficacy as central concerns. The implications for patient care include enhanced access to innovative treatments through strategic industry collaborations and regulatory facilitation of generics while maintaining stringent safety standards across drug development processes—all contributing towards advancing patient outcomes worldwide.Support the show

Colostrum used to be a staple for gut and immune support, but if you've noticed product quality drifting, labels getting vague, or patients reacting poorly, you're not imagining it. I sit down with Dr Chris Warner from Proliant Health and Biologics to unpack why Immunolin has become one of my preferred tools when I want consistent results and better tolerability, especially for people with fragile digestion.We break down what Immunolin actually is in plain terms: a serum-derived bovine immunoglobulin protein isolate, manufactured to deliver a standardised, high-IgG powder. From there, we get practical about what matters in clinic, including why raw material consistency changes everything for dosing, and why issues like lactose content and even endotoxin contamination can make some colostrum products a poor fit for patients who are already dealing with bloating, diarrhoea, gut inflammation, or suspected permeability problems.The most fascinating part is the mechanism. Chris explains how IgG can bind and neutralise antigens like LPS (endotoxin), helping reduce translocation across a “leaky” gut barrier and interrupt the inflammation loop. We also talk through where this may fit across IBS, IBD, SIBO, Crohn's and other hard-to-treat cases, plus how dosing can shift from a short “get you back on track” phase to longer maintenance. We finish by exploring the gut-brain axis, microbiome modulation, and why Immunolin can work alongside probiotics, prebiotics, and other microbiome strategies rather than replacing them.If you're a practitioner, or a curious patient who wants the why and the how, this is a grounded, research-informed listen. Subscribe, share with a colleague, and leave us a review so more people can find the conversation.For more information or to get in contact with Dr. Chris Warner:https://www.linkedin.com/in/christopher-warner-phd/https://www.linkedin.com/company/phb1/https://phb1.com/Shownotes and references are available on the Designs for Health websiteRegister as a Designs for Health Practitioner and discover quality practitioner- only supplements at www.designsforhealth.com.auFollow us on SocialsInstagram: DesignsforhealthausFacebook: DesignsforhealthausDISCLAIMER: The Information provided in the Wellness by Designs podcast is for educational purposes only; the information presented is not intended to be used as medical advice; please seek the advice of a qualified healthcare professional if what you have heard here today raises questions or concerns relating to your health

This week on The Pharma Letter Podcast, we're joined by Morten Graugaard, chief executive of Orbis Medicines: a Danish-Swiss biotech working to turn biologic-like medicines into oral therapies.Founded out of Novo Holdings' company creation work, Orbis is developing a platform for oral macrocycles, aiming to tackle one of drug development's stubborn problems: how to make complex, powerful molecules work as pills.The company's nGen platform combines high-throughput macrocycle chemistry with computational design, with the goal of moving beyond slow, bespoke discovery toward a more programmable approach.Orbis has attracted strong backing from life sciences investors, including Novo Holdings, Forbion, NEA and Lilly Ventures, and raised a 90 million euro Series A in 2025 to advance its platform and pipeline.Mr Graugaard brings the perspective of both an operator and an investor, having previously worked at Novo Holdings on life sciences investing, R&D strategy and company creation.In this episode, we discuss the shift from injectable biologics to oral therapies, the scientific hurdles still facing the field, what pharma companies are looking for in next-generation oral medicines, and how investor appetite is changing for ambitious platform biotechs.

Aspirin or biologics? How do you choose the right treatment for AERD? On this episode of the BackTable ENT & Allergy Podcast, Dr. Basil Kahwash interviews Dr. Andrew White, Director of the AERD Clinic at Scripps Clinic, to discuss the diagnosis and management of this often underrecognized condition. They cover practical strategies for identifying AERD, the importance of a detailed NSAID history, and how treatment decisions are shaped by patient goals and disease severity. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:08 - What Is AERD and Prevalence 06:32 - History Taking and Mechanism 11:10 - Typical Symptom Progression and Alcohol Intolerance 16:41 - When to Do Aspirin Challenge 19:00 - Challenge Protocol And Upper Airway Reactions24:53 - Aspirin Desensitization vs Challenge27:58 - Aspirin therapy after desensitization and Risk of GI Bleeds31:17 - Biologics Change AERD33:42 - Choosing Aspirin Desensitization vs Biologics 35:52 - Patient Counseling and Motivational Interviewing 41:26 - Convenience and Cost of Therapy 44:10 - ENT Allergy Collaboration47:22 - Rapid Fire Pearls51:13 - Future Research & Management Direction54:05 - Final Takeaways --- More about this episode Dr. White explains that AERD affects about 8 to 10 percent of asthmatics, with even higher rates in those with severe asthma or nasal polyps. He reviews typical adult-onset progression, alcohol-related respiratory symptoms, and the underlying pathophysiology, including imbalances in arachidonic acid mediators and leukotriene surges after NSAID exposure.The conversation includes practical questions to ask when taking an NSAID history, such as reactions to common pain relievers or alcohol, and when to consider aspirin challenge. Dr. White also details long-term treatment strategies, including the role of biologics like dupilumab and aspirin therapy after desensitization, with considerations for dosing and gastrointestinal risk. He explains how factors like asthma severity, recurrent polyp disease, sense of smell, cost, and convenience all influence therapy choice. The episode concludes with a discussion of multidisciplinary collaboration, patient counseling, and Dr. White's insights on future research directions in AERD management. --- Resources Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthmahttps://pubmed.ncbi.nlm.nih.gov/16275362/ Polyphenolic Activation of Basophils Explains Alcohol Hypersensitivity in AERDhttps://pubmed.ncbi.nlm.nih.gov/41065188/ New insights into the mechanisms of aspirin-exacerbated respiratory diseasehttps://pubmed.ncbi.nlm.nih.gov/39641750/ The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunologyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7980229/ Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center studyhttps://pubmed.ncbi.nlm.nih.gov/28550988/ Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory diseasehttps://pubmed.ncbi.nlm.nih.gov/17208597/ Factors influencing aspirin therapy after desensitization (ATAD) tolerance in aspirin-exacerbated respiratory disease (AERD) patientshttps://pubmed.ncbi.nlm.nih.gov/41022281/ Feed the Good Wolf: Motivational Interviewing, Cognitive Behavioral Therapy, and Mindsethttps://pubmed.ncbi.nlm.nih.gov/42103433/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

At CDMO Live Europe 2026, Jeff Mason, VP and Head of US Sales at Samsung Biologics, demonstrated a risk-based, parallel approach to dual-site technology transfer that delivered a first GMP batch at a second facility within 90 days of initiation.Read the full article.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of drug manufacturing, regulatory affairs, and scientific breakthroughs that are shaping the future of patient care and therapeutic innovation. Bristol Myers Squibb has made headlines with its substantial $2.3 billion investment in a new manufacturing campus in Houston. This strategic move aims to significantly bolster their capabilities across various modalities including small molecules, biologics, and antibody-drug conjugates. The establishment of this facility is a testament to the growing demand for advanced manufacturing infrastructure needed to support complex therapeutics production. As BMS strengthens its operational capacity, it positions itself to better meet the increasing global demand for innovative treatments. In parallel developments, Jazz Pharmaceuticals is expanding its rare epilepsy pipeline through a $1.3 billion acquisition of Actio Biosciences. This strategic acquisition aligns with Jazz's focus on rare diseases with significant unmet medical needs. By integrating Actio's novel small molecule approach, Jazz aims to leverage these innovative therapies to improve patient outcomes in the rare epilepsy market, highlighting a critical shift towards targeted treatments. Vaderis Therapeutics has successfully raised $152 million in Series B funding, aimed at advancing its AKT-targeting treatment for hereditary hemorrhagic telangiectasia (HHT). This funding will support clinical development efforts, offering hope for patients with this rare vascular disorder who currently have limited therapeutic options. The advancement of such targeted therapies underscores the growing focus on addressing rare diseases within the biotech sector. Clinical trial advancements remain pivotal, with MoonLake Immunotherapeutics reporting positive Phase 3 data for sonelokimab, an IL-17A/F inhibitor targeting psoriatic arthritis. This nanobody-based antibody offers a novel mechanism of action by modulating autoimmune pathways involved in psoriatic arthritis, demonstrating the potential of biologics in managing complex autoimmune conditions. In a transformative approach to drug discovery, Aureka Biotechnologies has raised $100 million in Series B funding to further its platform-enabled efforts in antibody and protein design using AI and machine learning technologies. This integration represents a significant step forward, enhancing efficiency and precision in identifying viable therapeutic candidates. Despite these advancements, regulatory challenges persist. The FDA recently rejected ITM Isotope Technologies' application for 177Lu-edotreotide due to manufacturing concerns related to gastroenteropancreatic neuroendocrine tumors. Such setbacks underscore the critical importance of robust manufacturing practices and regulatory compliance to ensure patient safety and product efficacy. BridgeBio and Alnylam Pharmaceuticals are engaged in a competitive race targeting first-line ATTR-CM patients with differing therapeutic approaches—“silencer” versus “stabilizer” therapies. This debate highlights the intricacies involved in treating transthyretin amyloidosis (ATTR), a condition affecting the heart and nervous system, pointing towards potential breakthrough treatments that could significantly improve patient outcomes. On the regulatory front, President Donald Trump has signed an executive order aimed at revising pediatric vaccine recommendations, reflecting a shift in public health policy that could affect vaccination rates and parental decision-making regarding childhood immunizations. WuXi AppTec recently secured a temporary victory in its legal battle with the U.S. Department of Defense regarding its classification as a Chinese military company. This case highlights the geopolitical complexities faced by global pharmaceutical companies operating in sensitive markets. Meanwhile, technological innovation continues to shape healthcare delivery, exemplified by Abbott's partnership with Google Health to develop an AI-powered health insights application. This collaboration is part of a growing trend toward integrating digital technologies into healthcare to enhance diagnostics and personalized medicine. Finally, strategic corporate restructuring is evident as Aura Biosciences refocuses its R&D efforts on ocular oncology under new leadership. Such moves reflect broader trends within biotech firms to streamline operations and concentrate resources on high-potential therapeutic areas. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific innovation, strategic alliances, regulatory shifts, and technological integration—all aimed at advancing patient care and therapeutic efficacy in an increasingly complex global environment. As companies continue to navigate these challenges and opportunities, they are set to reshape the future of drug development with significant implications for patient outcomes worldwide.Support the show

Can viewing the airway as one connected system change the future of respiratory care and improve patient outcomes? On this episode of the BackTable ENT & Allergy Podcast, Dr. Cedric Jamie Rutland, pulmonary and critical care medicine physician, joins Dr. Basil Kahwash to discuss the unified airway hypothesis and its implications for clinical care. They explore how upper and lower airway inflammation are closely linked, and why multidisciplinary collaboration is essential for treating the whole patient. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction05:06 - Understanding the Unified Airway14:27 - Decoding Asthma Biomarkers20:34 - Endotyping in Clinical Practice26:36 - Addressing Asthma Symptom and “Outgrowing” Asthma32:13 - Strategies for Precision Biologics34:23 - Navigating Insurance and Treatment Indications35:36 - Treating the Whole Patient and Breaking Down Specialty Silos46:07 - Effective Patient Communication51:36 - Asthma Lightning Round57:33 - Biologics and Airway Remodeling1:00:00 - Closing Thoughts --- More about this episode The conversation covers the biology of type II inflammation, the use of biomarkers and biologics for more personalized treatment, and practical strategies for overcoming insurance barriers and specialty silos. Dr. Rutland shares insights on patient communication, the limitations of current diagnostics, and the impact of chronic inflammation on systemic disease. The episode highlights the need for ENT, allergy, and pulmonology teams to work together and embrace a connected view of airway disease to achieve better patient outcomes. --- Resources Dr. Jamie Rutland - https://www.lung.org/media/meet-our-experts/cedric-jamie-rutland-md --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Jimmy Chang, Chairman and CEO of TaiMed Biologics,  is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an alternative to daily oral medications, while minimizing enzymatic metabolism and associated drug interactions. While successful treatments for HIV have shifted the focus from survival to quality of life and managing a chronic condition, new challenges have emerged to ensure patient convenience and adherence.  Jimmy explains, "TaiMed is a biotech company based in Taiwan. Our focus is to develop innovative product for the HIV. And actually, over the years we have developed the first CD4-directed antibody for HIV treatment, and the product was approved in the US. And today we are currently focusing on developing the CD4-targeting antibody in a combination for long-acting HIV treatment."   "So in today's world, HIV therapies, HIV patients, or the people living with HIV, the field is HIV as a chronic disease. The patient can live longer and healthier just like everybody else. However, it requires dedication and commitment to medication because there's no cure today. HIV, the virus keeps mutating. So if the disease is not under control, this could be problematic, and basically one day the patient may run into a situation where most of the drugs do not work for the patient." "So in the earlier days, the innovations or the medications were mainly trying to have the virus under control, with the focus of the medications. And so nowadays, because people living with HIV actually have a very good health condition, just like typical individuals live longer and healthier. So this comorbidity, or we call it the polypharmacy drug-drug interaction, is really the challenge that the physicians or patients have to face every day. And with our innovations, we believe we have the opportunity to offer another innovative medication to specifically address those challenges." #TaiMed #HIVCare #LongActingTherapies #AntibodyTherapeutics #CD4 #Polypharmacy #InfectiousDiseases #TaiMedBiologics #EmpoweredPatient #HealthcareInnovation taimedbiologics.com Download the transcript here 

Jimmy Chang, Chairman and CEO of TaiMed Biologics,  is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an alternative to daily oral medications, while minimizing enzymatic metabolism and associated drug interactions. While successful treatments for HIV have shifted the focus from survival to quality of life and managing a chronic condition, new challenges have emerged to ensure patient convenience and adherence.  Jimmy explains, "TaiMed is a biotech company based in Taiwan. Our focus is to develop innovative product for the HIV. And actually, over the years we have developed the first CD4-directed antibody for HIV treatment, and the product was approved in the US. And today we are currently focusing on developing the CD4-targeting antibody in a combination for long-acting HIV treatment."   "So in today's world, HIV therapies, HIV patients, or the people living with HIV, the field is HIV as a chronic disease. The patient can live longer and healthier just like everybody else. However, it requires dedication and commitment to medication because there's no cure today. HIV, the virus keeps mutating. So if the disease is not under control, this could be problematic, and basically one day the patient may run into a situation where most of the drugs do not work for the patient." "So in the earlier days, the innovations or the medications were mainly trying to have the virus under control, with the focus of the medications. And so nowadays, because people living with HIV actually have a very good health condition, just like typical individuals live longer and healthier. So this comorbidity, or we call it the polypharmacy drug-drug interaction, is really the challenge that the physicians or patients have to face every day. And with our innovations, we believe we have the opportunity to offer another innovative medication to specifically address those challenges." #TaiMed #HIVCare #LongActingTherapies #AntibodyTherapeutics #CD4 #Polypharmacy #InfectiousDiseases #TaiMedBiologics #EmpoweredPatient #HealthcareInnovation taimedbiologics.com Listen to the podcast here 

The latest episode of the DDW 'In Conversation With' series is available to listen to below. This week, Bruno Quinney speaks to Reuben Dawkins, CEO of Link Biologics, a company developing protein biologics to treat inflammatory and degenerative conditions. Link is currently developing treatments for Dry Eye Disease and Wet AMD. Bruno chats to Reuben about why Link chose to target Dry Eye Disease with its pioneering approach, how the company saw an opportunity to compete with current treatments for Wet AMD, and whether the science behind Link's protein biologics could be used beyond ophthalmology. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.  

Naturopathic gastroenterologist Mark Davis, ND (FABNG), discusses his work in fecal microbiota transplantation (FMT), research, and integrative approaches to GI disease. Davis explains FMT history, screening criteria, delivery methods, how it differs from probiotics, and why it is highly effective for recurrent C. difficile (about a 90% durable cure), while noting FDA-approved products (Rebyota, Vowst) and off-label applications. He describes IRB-approved studies on naturopathic care for IBS and ulcerative colitis and a blinded project comparing consistency across 15–20 stool microbiome labs. The conversation covers evidence for diet in IBS/IBD (including SCD and a semi-vegetarian diet), low-FODMAP as a temporary tool, breath testing and relapse in SIBO, helminthic therapy options and legality, targeted probiotics (Saccharomyces boulardii, Akkermansia, soil-based species), enema therapies, indigo naturalis benefits and risks, saffron evidence for mood, telemedicine practice, and a crowdfunding platform for clinical trials.

In this episode, host Dr. Kristine Smith speaks with Dr. Leigh Sowerby. They discuss the recently published Clinical Letter: “Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis”. The full manuscript is available as open access in the International Forum of Allergy and Rhinology. Listen and subscribe for free to […]

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs like Ultomiris. The company's confidence is further reflected in its robust internal pipeline of antibody-drug conjugates (ADCs), even after discontinuing two candidates that fell short in clinical trials. This move highlights an industry-wide focus on high-potential therapeutic areas, underscoring the critical role of sustained innovation in preserving market leadership. In leadership news, Sarepta Therapeutics has appointed Michael Severino as CEO, succeeding Doug Ingram. Severino's extensive experience from AbbVie and Tessera signals a strategic shift for Sarepta, especially as it hones its focus on therapies for Duchenne Muscular Dystrophy. Leadership transitions like this can significantly impact a company's strategic direction, potentially steering it toward new therapeutic breakthroughs. On the regulatory front, Otsuka's Simtriyo has received FDA approval, marking it as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. This approval is a major leap forward in central nervous system therapeutics, offering a non-stimulant option that could become a blockbuster drug in this underserved market. Such advancements highlight the persistent need for innovative treatments in CNS disorders. Similarly, Outlook Therapeutics has achieved FDA approval for Lytenava, a reformulated version of Roche's Avastin for wet age-related macular degeneration (AMD). This victory, following three prior rejections, exemplifies the challenges and opportunities inherent in drug reformulation and regulatory perseverance. Corporate acquisitions continue to shape industry dynamics. Argenx's acquisition of Forte Biosciences for $2.2 billion exemplifies strategic investments aimed at expanding therapeutic portfolios. Forte's promising Phase 2-stage vitiligo drug acquisition underscores the industry's shift towards biologics in managing complex autoimmune disorders. Amgen's recent layoff of approximately 40 employees aligns with broader trends of operational optimization amidst organizational restructuring. Such workforce adjustments often reflect shifts in business strategy or responses to evolving market conditions. In clinical development news, InnoCare Pharma has announced successful Phase 3 results for its oral TYK2 inhibitor Fadeucravacitinib in treating moderate-to-severe plaque psoriasis. This achievement underscores the potential of targeted therapies in addressing autoimmune conditions by modulating specific signaling pathways. The FDA's approval of Freenome's SimpleScreen CRC blood test marks a significant advancement in non-invasive diagnostic tools for colorectal cancer screening. Such innovations could dramatically impact early cancer detection and improve patient outcomes. Meanwhile, emerging insights into CAR-T therapy have identified genetic markers linked to toxicity risks in Yescarta patients. These findings can guide future CAR-T product development towards enhanced safety profiles, offering pathways for engineering safer therapies by identifying patients at higher risk for adverse effects. Finally, the partnership between Salesforce and Veterans Affairs aims to integrate AI into healthcare workflows, illustrating the increasing role of digital transformation in enhancing healthcare delivery and operational efficiency. These developments highlight the ongoing evolution towards more personalized and efficient healthcare solutions within the pharmaceutical and biotech sectors. As companies navigate complex regulatory landscapes, pursue innovative therapies, and adapt to dynamic market demands, their efforts are poised to advance patient care standards and drive future growth within these critical industries. The implications for patient care are profound, as new treatments offer hope for conditions that have long eluded effective intervention. Stay tuned with Pharma Daily as we continue to bring you the latest updates from this rapidly evolving field.Support the show

Today's episode is about allometric scaling with therapeutic antibodies. I discuss differences from small molecules, how to handle antibodies with engineered Fc regions (e.g. YTE or LS), and using allometry to extrapolate from adults to pediatrics for these antibodies. Links discussed in the show:Haray and Tachibana's article on allometric exponents for monoclonal antibodies Exponents for standard antibodies: CL = 0.8, Q = 0.75, Vc = 1/.0, Vp = 0.95Exponents for modified antibodies: CL = 0.55, Q = 6, Vc = 0.95, Vp = 0.95You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

Fatigue with biologics… and with Jake Loose, PA-S! [article]Toxic erythema of chemotherapy [article]Juxta-clavicular beaded lines [article]Managing facial hyperpigmentation [article]Want to expand your dermatology knowledge? Check out Summit Derm here!⁠https://medicine.utah.edu/dermatology/education/cme-opportunities/summit⁠Learn more about the U of U Dermatology ECHO model!https://physicians.utah.edu/echo/dermatology-primarycareWant to donate to the cause? Do so here!Donate to the podcast: ⁠⁠uofuhealth.org/dermasphere⁠⁠Check out our video content on YouTube:⁠⁠www.youtube.com/@dermaspherepodcast⁠⁠and VuMedi!: ⁠⁠www.vumedi.com/channel/dermasphere/⁠⁠The University of Utah's DermatologyECHO: ⁠⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠⁠ Connect with us!- Web: ⁠⁠⁠dermaspherepodcast.com/⁠⁠⁠ - Twitter: @⁠DermaspherePC⁠- Instagram: dermaspherepodcast- Facebook: ⁠⁠www.facebook.com/DermaspherePodcast/⁠⁠- Check out Luke and Michelle's other podcast,SkinCast! ⁠⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠⁠⁠www.levelex.com/games/top-derm⁠⁠⁠ (A free dermatology game to learn more dermatology!

Curious about a flexible, high-paying nonclinical career that still uses your medical expertise? In this episode, I'm joined by Dr. Keagen Hadley, an occupational therapist who built a successful career in regulatory medical writing without ever stepping into clinical practice. Dr. Hadley shares how he discovered this little-known field while working in clinical research, the persistence it took to break in, and why regulatory writing can be such an appealing option for physicians seeking flexibility, meaningful work, and strong earning potential. We also explore what regulatory writers actually do, who tends to thrive in this role, how AI is impacting the profession, and practical strategies for getting started. If you enjoy structure, attention to detail, and helping bring new therapies to patients, this conversation may open your eyes to an exciting career path you hadn't considered. In this episode we're talking about: What regulatory medical writing is and its role in drug, biologic, and device development The personality traits and skills that help people succeed in regulatory writing Dr. Keagen Hadley's unconventional path from occupational therapy to a thriving writing career How physicians can break into the field through networking, recruiters, and strategic positioning Compensation, flexibility, and career growth opportunities in regulatory writing How AI is influencing regulatory writing and why human expertise remains essential Resources, training recommendations, and practical advice for exploring this career path You can find the show notes for this episode and more information by clicking here: www.doctorscrossing.com/episode251 Links for this episode: The Clinician's Guide to Regulatory Writing | Keagen Hadley | Substack  Keagen Hadley | LinkedIn  Targeted Regulatory Writing Techniques: Clinical Documents for Drugs and Biologics by Wood and Foote 6 Month Road Map to Becoming a Regulatory Writer by Keagen Hadley Regulatory Medical Writing Masterclass  Medical Writing Resource Guide – This 11-page guide gives you an introduction to medical writing as well as links for courses, books, websites, and tips for exploring this diverse area. Includes steps you can take whether you want to do medical writing as a side gig, or work full-time as a freelancer or an employee. Land Your Dream Job With LinkedIn: 5 Steps To Get Started – Following these 5 tips will help you optimize your profile, connect and network with others, and have success applying to jobs on LinkedIn! Thank you for listening!

Congress reopens MKUltra. MIT hands over a 74-year-old recording tied to UFOs buzzing the Capitol in 1952. Whistleblower amnesty for recovered biologics moves forward. A military base couldn't keep unidentified objects out of its airspace for 17 straight days.Luna's task force hauled a retired CIA officer before Congress to explain how the agency dosed Americans with LSD for twenty years without consent, then burned the paperwork. A CIA safe house in Germany may hold remains of some of those subjects.MIT Lincoln Laboratory's 74-year-old recording is tied to the 1952 UAP incursion over Washington DC. A senator is building legal cover for whistleblowers to discuss recovered alien biologics.Two Casias updates. New evidence at recovery site. Fellow missing Los Alamos worker Anthony Chavez spent his final weeks researching whether matter can exist in two places at once.Patreon: https://patreon.com/InfiniteRabbitHoleJeremy's Book: https://www.amazon.com/U-F-Elmwood-Cosmic-Puzzle/dp/B0GX1GBMZNYouTube: https://www.youtube.com/@InfiniteRabbitHolePodcastWebsite: https://InfiniteRabbitHole.com

In this episode of Denatured, you'll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJack Crawford, CEO, DemeetraMagnus Gustafsson, Chief Commercial Officer, NorthX BiologicsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Drs. Shahriari and Bunick discuss the emerging promise of bi- and tri-specific biologics for atopic dermatitis, aiming to bridge the gap between highly targeted biologics and broad JAK inhibitors by more comprehensively blocking key cytokine pathways. They highlight early data, such as with galvokimig, suggesting potentially higher efficacy and the possibility of improved safety and reduced paradoxical side effects, while emphasizing that final positioning in treatment will depend on forthcoming phase 2 and 3 trial results.

Sean Hazlett joins us today to talk about the official disclosure plan. We'll review supernatural phenomena, religious rituals for contacting UFOs, and other interesting topics. Welcome to Camp!

Drs. Newhall and Gupta discuss how biologic therapies are transforming care for patients with multiple allergic diseases—such as asthma, atopic dermatitis, nasal polyps, food allergy, and eosinophilic esophagitis—while also making treatment decisions more complex. They explain how they choose among biologics like dupilumab, omalizumab, IL‑5 blockers, and TSLP inhibitors by focusing on biomarkers, age, comorbidities, and which condition most affects the patient's quality of life.

SUMMARY DEL SHOW Futuros ligeramente al alza este martes extendiendo el rally del lunes, con el Dow en récord sobre 52,000 puntos y el mercado atento al JOLTS, la confianza del consumidor y los resultados de Nike después del cierre. $MSTR rompe oficialmente su política de "nunca vender" Bitcoin tras acumular $32 Billones en pérdidas no realizadas, autorizando ventas de BTC para cubrir dividendos, deuda y recompras. $AMZN extiende sus promociones de verano tras confirmarse que superó a Walmart como el minorista más grande de EE.UU., mientras $LLY firma un acuerdo de distribución con Innovent Biologics para su oncológico Verzenios en China.

In this first deep dive, Christopher Cogle explores the evolving landscape of acute myeloid leukaemia (AML). He discusses the challenge of translating research into real-world outcomes, emerging immunotherapies, precision diagnostics, and how innovations such as the Acute Leukemia Methylome Atlas may reshape AML management in the future.  Timestamps:  00:55 – Research Gaps  03:50 – Biologics  05:46 – AML Atlas  09:15 – Immunotherapy 

In this episode of the UConn Internal Medicine Podcast Series, we discuss the evolving role of biologic therapies in asthma and COPD. We review how biologics target Type 2 inflammation, how to identify patients with severe asthma who may benefit from therapy, and how biomarkers such as blood eosinophils, FeNO, IgE, and allergic sensitization guide treatment selection.We also explore newly approved biologics for COPD, practical differences between available agents, expected benefits, steroid-sparing effects, safety considerations, pregnancy counseling, helminth screening, and real-world barriers such as cost and insurance approval.This episode is designed for internal medicine trainees and clinicians looking for a practical framework to understand when to consider biologics, how to choose the right agent, and what to monitor after starting therapy.Hosts:Dr. Hossam Albeyoumi Mohammed, and Dr. Simran Umra, Chief Medicine Residents, UConn.Dr. Alisa Pasichnik, and Dr. Caroline McCauley, 3rd year medicine residents, UConn.Guests:Dr. Ethan Bernstein, Associate Program Director of the Department of Pulmonary and Critical Care Medicine, UConn.Dr. Angela Quental, incoming Assistant Professor in the Department of Pulmonary and Critical care medicine, UConn.Edited by:Dr. Hossam Albeyoumi Mohammed, Chief Medicine Resident, UConn.Music:LoFi Girl by Snoozy Beats | Free Music Archive | Livense: CC BY.

An update on my thoughts on treatment of IBD in 2026. 

Rep. Anna Paulina Luna said today that UAP whistleblowers will provide locations of UFO craft and non human biologics. The fear of losing clearance might not be an issue if the White House gives them immunity. Will this be effective? Kristian Harloff gives his thoughts.

Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alternative expression platforms and offers a clear, practical framework for scientists navigating host cell decisions today. David Brühlmann moves past simplistic "replacement" narratives to instead examine where each technology, from plant farming to cell-free systems, fits in today's market and production realities.Key topics discussedWhy asking if a novel host will "replace CHO" is the wrong question for scientists and manufacturers (00:11)Critical dimensions to evaluate: cost structure, speed, and intrinsic product quality (01:20)Review of five alternative platforms with current clinical and regulatory status: Plant farming for speed and decentralization (03:42)Insect cells for VLPs and complex proteins (05:00)Cell-free protein synthesis for ADCs and unique conjugation requirements (06:23)Moss for monoclonal antibodies with distinct glycosylation patterns (07:50)Filamentous fungi for high secretion and thermotolerance (08:47)A practical host selection framework by molecule type and manufacturing context (09:59)Detailed constraints and advantages of each platform, including cost, infrastructure, timeline, and product attributes (10:09)Analysis of silkworm production as a disruptive possibility for future biologics manufacturing (13:09)The evolving toolkit available to bioprocess scientists—and why "CHO replacement" is a distraction from more relevant questions (12:06)Smart insight:The real development over the past decade is that bioprocess scientists now have a credible, validated toolkit of alternatives for specific molecules in specific contexts. The practical implication: know this landscape well enough to ask the right host selection question at program initiation, before you've built months of process development around a platform you chose by default.Here are the episodes referenced:Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo PhoolcharoenEpisodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi OsawaEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranNext:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

The buzz around stem cells and exosomes continues to grow, but so do the legal and regulatory questions. In this fan favorite episode, Dr. Jordan Plews shares what medical practices should understand about these products, including FDA concerns, off-label risks, and why compliance matters just as much as innovation.Chapters[00:00] Intro[01:06]  Banter  [04:56]  Guest background[09:40]  What are stem cells and exosomes?[11:00] What is the use risk for live cells and a stem cells?  [13:00] Is there a product out there similar to stem cells?  [15:30] Can a medical practice offer stem cells or exosomes?[18:44] What are the risks of offering stem cells and exosomes?[20:08] What are patient and provider risks of stem cells and exosomes?[22:00] How are medical practices using stem cells and exosomes?[23:00] How would you advise practices looking to offer stem cells and exosomes?[26:51] Access+[27:26]  Legal Takeaways  [30:26]  OutroWatch full episodes of our podcast on our YouTube channel: https://www.youtube.com/@byrdadattoStay connected for the latest business and health care legal updates:WebsiteFacebookInstagramLinkedIn

Andy gives his immediate post-press conference thoughts following David Grusch, members of Congress, Leslie Kean and others speaking on the steps of Capitol Hill.This episode covers the key moments from the event, including calls for whistleblower protections, pressure on President Trump to waive NDAs, renewed talk of non-human biologics, and Grusch's striking comments about a spectrum of life ranging from corporeal bipedal beings to “sentient plasmoid life.” Andy also looks at the mixed reaction to the event, the role of mainstream media, what this could mean for future disclosure efforts, and where things may go next.Plus, Andy shares thoughts on upcoming interviews with Jeremy Corbell and Richard Dolan, the wider media landscape, and why this moment may be more important than it first appeared.

At this year's PEGS Boston, industry experts gathered on a panel to explore how AI and machine learning are deployed in biologics R&D today. Moderated by Peter M. Tessier, Ph.D., Albert M. Mattocks professor of pharmaceutical sciences and chemical engineering at University of Michigan, the panel consisted of Andrew Buchanan, Ph.D., head of discovery at a stealth-mode biotech company; Norbert Furtmann, Ph.D., head of biologics AI and design of large molecules research at Sanofi; Konrad S. Krawczyk, Ph.D., founder and CSO at NaturalAntibody SA; Andrew C.R. Martin, Ph.D., emeritus professor of bioinformatics and computational biology at University College London; Melody Shahsavarian, Ph.D., senior director of data strategy and digital transformation of biotherapeutics discovery research at Eli Lilly & Company; and Bernhardt L. Trout, Ph.D., professor of chemical engineering at Massachusetts Institute of Technology.  Links from this episode:  Pharmaceutical Sciences & Chemical Engineering, University of Michigan University of Michigan Sanofi NaturalAntibody SA Bioinformatics, UCL Biosciences Computational Biology, UCL University College London   Eli Lilly & Company 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements shaping the landscape of our industry. As technology continues to redefine traditional paradigms, the collaboration between Pfizer and Chai Discovery exemplifies this trend. By harnessing artificial intelligence, particularly through custom models like Chai-3, this partnership aims to revolutionize drug discovery. The integration of AI promises not only to accelerate the identification of biologics and antibodies but also to optimize resource allocation in research and development. Such technological integration could pave the way for an enhanced pipeline of innovative treatments, marking a transformative shift in how therapeutic candidates are developed. In the realm of regulatory developments, Lupin's Ranluspec has recently received FDA approval as an interchangeable biosimilar targeting VEGF-A for various retinal conditions. This move underscores the importance of biosimilars in providing cost-effective alternatives to expensive biologics, thereby expanding patient access to essential treatments for conditions like macular degeneration. Additionally, the MHRA's marketing authorization for Aujemflu, an adjuvanted trivalent influenza vaccine for adults aged 50 and over, reflects ongoing efforts to bolster protection against infectious diseases among vulnerable populations. Clinical trial advancements continue to highlight significant progress in therapeutic development. Otsuka Pharmaceuticals' Phase 3 data on Voyxact has shown promising stabilization of kidney function in patients with Immunoglobulin A nephropathy. This protein therapy targets autoimmune pathways, offering new hope for managing this chronic kidney condition. Similarly, Autobahn Therapeutics' Elunetirom has advanced to a pivotal trial following Phase 2 success in treating bipolar depression. This showcases the potential of small molecule therapies targeting thyroid hormone receptors. Meanwhile, Hikma Pharmaceuticals' victory in a landmark patent case regarding skinny labels marks an important development in pharmaceutical intellectual property rights. The unanimous Supreme Court ruling against Amarin supports the legitimacy of using skinny labels to market generic versions of drugs for non-patented indications. This decision could enhance market competition and drive down healthcare costs, setting a precedent for future intellectual property disputes. On the business front, strategic partnerships and mergers continue to shape industry dynamics. Gilead Sciences' acquisition of Ouro Medicines for $1.675 billion strengthens its autoimmune inflammation pipeline. This transaction exemplifies how major deals are reshaping therapeutic portfolios in response to growing demand for treatments targeting rare diseases. Financially, Solix Pharmaceuticals' success in raising $71 million to advance its siRNA pipeline across multiple therapeutic areas demonstrates investor confidence in RNA-based therapeutics as a promising frontier for innovative treatments. Conversely, challenges persist as evidenced by Takeda's $2.5 billion legal provision over an antitrust case related to Amitiza, underscoring ongoing financial risks associated with litigation in the pharmaceutical sector. Corporate restructuring also signals shifts within the industry landscape. Fulcrum Therapeutics' decision to lay off 85% of its workforce following the discontinuation of its sickle cell disease candidate highlights the volatility and high stakes inherent in drug development. Overall, these developments illustrate a dynamic landscape where scientific innovation is propelled by AI-driven approaches and strategic collaborations while regulatory victories and financial maneuvers shape market dynamics. These trends have profound implications for patient care by potentially accelerating the availability of novel therapies and fostering a competitive environment that drives down costs. As we look ahead, stakeholders must navigate these complexities effectively to harness opportunities and address challenges within this rapidly evolving industry landscape. The ability to adapt and capitalize on emerging trends will be crucial as these sectors continue to evolve, ultimately enhancing patient care and advancing therapeutic frontiers globally. Thank you for joining us today on Pharma Daily; stay tuned for more insights into the ever-changing world of pharmaceuticals and biotech.Support the show

In this episode of BioTalk with Rich Bendis, Jeffrey N. Hausfeld, M.D., Chairman of the Board and Chief Medical Officer of BioFactura Inc., and Darryl Sampey, Ph.D., President and Chief Executive Officer of Capitol Biologics, join the conversation to discuss the launch of Capitol Biologics as BioFactura's CDMO division. Jeff and Darryl explain how BioFactura's experience building biologics development and clinical manufacturing capabilities created the foundation for a more personalized CDMO model. The discussion explores the gap Capitol Biologics is designed to fill for emerging biotech companies that need integrated development support, scientific depth, analytical expertise, phase-appropriate quality, and early GMP manufacturing without being pushed into a large commercial-scale CDMO model too soon. The conversation also highlights what biotech CEOs and CMC leaders should consider before choosing a CDMO partner, including developability assessment, cell line and process development, analytical characterization, quality systems, cost of goods, regulatory readiness, and timing. Jeff and Darryl also discuss the growing importance of U.S.-based biologics development and manufacturing capacity, especially for emerging biotech and government-aligned programs. Editing and post-production work for this episode was provided by The Podcast Consultant. Jeffrey N. Hausfeld, M.D., M.B.A., F.A.C.S., is a physician entrepreneur, biotechnology executive, investor, and healthcare innovator whose career spans clinical medicine, life sciences, healthcare real estate development, and entrepreneurial leadership. A graduate of Yale University School of Medicine and recipient of an M.B.A. from Johns Hopkins University, Dr. Hausfeld is an Associate Clinical Professor of Surgery at George Washington University and has been actively involved in national medical societies and healthcare leadership organizations for more than four decades. He currently serves as Chairman of the Board and Chief Medical Officer of BioFactura Inc., Chairman of Capitol Biologics, and Chairman and Co-Founder of the Society of Physician Entrepreneurs. His work focuses on advancing healthcare innovation, biotechnology commercialization, physician entrepreneurship, and the responsible adoption of emerging technologies that improve patient care. Darryl Sampey, Ph.D., is a biopharmaceutical executive and company builder with more than 30 years of experience advancing biologics from discovery through clinical development and commercial manufacturing. He co-founded BioFactura in 2004 and has guided the company from start-up through incubator stages into a fully integrated biopharmaceutical product development and clinical manufacturing company. At BioFactura, he has raised more than $90 million in non-dilutive and strategic funding, built cGMP manufacturing capabilities, and led development of novel therapeutics, biodefense medical countermeasures, biosimilars, and cell therapies. Dr. Sampey is an inventor of the VeriCyte™ Discovery and StableFast™ Biomanufacturing Platforms and previously held process development and manufacturing leadership roles at Human Genome Sciences and North American Vaccine.

Allergy treatment is evolving beyond antihistamines. Discover how new biologics, immunotherapy, and microbiome-based therapies are targeting the root immune response for long-term relief, and what you should ask your allergist about these game-changing options. WhatAreAllergies.com City: Dallas Address: 3145 Olive Street Website: https://whatareallergies.com

When it comes to treating chronic sinus disease with nasal polyps…what's the best approach, surgery or biologics?Well, the answer is it's usually not either-or anymore.When patients are trying to manage these challenging conditions, some people opt for one or the other. But more physicians are finding that surgery and biologics aren't different paths. They are actually treatment protocols that complement each other.Surgery may remove the growths, but it doesn't necessarily stop the process of creating them in the first place. Biologics may suppress the inflammatory pathways driving recurrence, but they don't physically restore blocked sinus anatomy or remove bulky disease.We're entering a new phase of care where the question is no longer “surgery or biologics?” but how both can work together as part of a personalized strategy.Instead of treating every patient the same way, physicians are now looking deeper at the inflammatory pathways driving disease, recurrence risk, quality of life, and even how different biologics target different parts of the immune cascade.The shift is moving chronic sinus care away from a one-size-fits-all model and toward precision medicine that's designed around the individual patient.In this episode, I'm joined by Dr. Tassos Hantzakos, staff physician in otolaryngology and residency program director at Cleveland Clinic Abu Dhabi, and Dr. Deepa Sheth, allergy and immunology specialist.Together, we break down how the treatment landscape for chronic rhinosinusitis with nasal polyps is evolving, why collaboration between ENT and allergy specialists is becoming essential, and how biologics are reshaping the future of inflammatory airway disease management.Things You'll Learn In This Episode Not just a surgical problemFor decades, treatment focused on physically removing nasal polyps, but many patients still experienced recurrence. Why does surgery alone often fail to stop the disease?Biologics are changing how we think about airway diseaseNew biologic therapies are targeting different parts of the inflammatory cascade. How do physicians decide which biologic is the best fit for a specific patient?The future of treatment is collaborative, not competitiveThe conversation is shifting away from “surgery versus biologics” toward integrated care between ENT surgeons and allergists. When should surgery come first, and when should biologics be introduced?Precision medicine is reshaping chronic inflammatory careDifferent patients may require different treatment approaches. How does identifying the root inflammatory driver completely change long-term management outcomes?Guest BioDr. Tassos Hantzakos is a staff physician in the Otolaryngology Department at Cleveland Clinic Abu Dhabi's Integrated Surgical Institute, where he also serves as Program Director of the Otolaryngology Residency. His clinical expertise spans otolaryngology, rhinology, phonosurgery, laryngeal laser surgery, and voice disorders. Before joining Cleveland Clinic Abu Dhabi, Dr. Hantzakos served as a consultant within the Hellenic National Health System, Director of the Voice Clinic at NUKA, and Clinical Associate Professor at Cleveland Clinic Lerner College of Medicine in the US. He has contributed to numerous international journal articles and textbooks and is actively involved in several professional societies, including the European Laryngological Society, the International Association of Phonosurgeons, the Voice Foundation, and the European Society for Swallowing Disorders. Outside of medicine, he enjoys spending time with his family, long-distance running, triathlons, and playing guitar and drums. Connect with him on LinkedIn. Dr. Dipa K. Sheth is an allergist-immunologist based in Washington, DC, and an Assistant Professor of Medicine at Uniformed Services University of the Health Sciences. Her clinical work focuses on allergy and immunology, with experience treating conditions such as chronic sinusitis, rhinitis, atopic dermatitis, drug hypersensitivity, and food hypersensitivity. Dr. Sheth received her medical degree and completed her internal medicine training at George Washington University, followed by a fellowship in Allergy and Immunology at the University of Colorado School of Medicine and National Jewish Health. Her research has been published in journals including Frontiers in Allergy and Current Opinion in Allergy and Clinical Immunology. Connect with her on LinkedIn. About Your HostHosted by Dr. Deepa Grandon, MD, MBA, a triple board-certified physician with over 23 years of experience working as a Physician Consultant for influential organizations worldwide. Dr. Grandon is the founder of Transformational Life Consulting (TLC) and an outspoken faith-based leader in evidence-based lifestyle medicine.Disclaimer ​​TLC is presenting this podcast as a form of information sharing only. It is not medical advice or intended to replace the judgment of a licensed physician. TLC is not responsible for any claims related to procedures, professionals, products, or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services, or methods that might be referenced.Work With Me Learn More About My Soon-to-Launch Telemedicine PlatformExciting news. My virtual medical platform is launching soon! If you're looking for personalized, evidence-based care in allergy, immunology, and lifestyle medicine, stay tuned. Visit drdeepa-tlc.org and click on “Learn More” to join the waitlist and be the first to receive updates about services, membership options, and launch details.Precision care. Personalized guidance. Wherever you are.Devotionals Want to receive a devotional every week from Dr. Deepa? Devotionals are dedicated to providing you with a moment of reflection, inspiration, and spiritual growth each week, delivered right to your inbox. Visit drdeepa-tlc.org to subscribe for free.Trauma Courses Ready to deepen your understanding of trauma and kick-start your healing journey? Explore a range of online and onsite courses designed to equip you with practical and affordable tools. From counselors, ministry leaders, and educators to couples, parents, and individuals seeking help for themselves, there's a powerful course for everyone. Browse all the courses now to start your journey.

What's changing in rheumatoid arthritis treatment in 2026? In this powerful conversation, Dr. Isabelle Amigues and Dr. Diana Girnita discuss the latest breakthroughs in rheumatoid arthritis care, including precision medicine, biologics, remission strategies, tapering medications, vagus nerve stimulation, stress reduction, and the future of autoimmune healing. They explore how rheumatology is evolving from simply managing symptoms to helping patients achieve full remission and improve overall quality of life. From methotrexate and biologics to meditation, breathwork, and nervous system regulation, this discussion highlights a more personalized approach to autoimmune disease treatment.If you're living with rheumatoid arthritis, autoimmune disease, chronic inflammation, or searching for new hope beyond traditional treatment models, this episode is for you.Topics discussed:• Rheumatoid arthritis treatment updates• Biologics vs JAK inhibitors• Precision medicine in rheumatology• Can patients taper off medication?• Vagus nerve stimulation for inflammation• Stress, nervous system & autoimmune disease• Direct care rheumatology• Full remission in RA• Lifestyle medicine & autoimmune healing• Future of rheumatology care

Former Pentagon AATIP director and whistleblower Luis Elizondo joins Jillian Michaels for one of the most explosive UAP conversations ever recorded. warning: the scientists connected to America's most sensitive aerospace and defense programs are disappearing. Some are dead. There is an active FBI investigation. In this episode, we break down everything Congress and the mainstream media are quietly confirming: alien hybrid breeding programs, UAP escorted by U.S. military jets, a secret government operating outside the constitutional chain of command, and CIA officers waking up on their back lawns with foreign objects embedded in their bodies. We also go deep on Project Stargate — the U.S. Army's classified remote viewing program that successfully located a crashed Soviet aircraft in Africa and beat the stock market by $2 million — and why Elizondo believes consciousness itself may be a quantum process. Topics covered: • Missing and murdered scientists linked to classified aerospace programs • Congressional testimony on alien hybrid breeding programs • The “shadow government” operating outside presidential oversight • CIA abduction cases with physical evidence • Remote viewing, Project Stargate, and why the Pentagon quietly still uses it • Trump's UAP declassification — and why people are furious it's not enough • Are UAPs demons? What the Vatican told Elizondo • Why full disclosure may already be happening — and what comes next Chapters 00:00 — Intro: Missing Scientists 01:24 — Whistleblower Security Threats 04:13 — Alien Hybrid Breeding 09:44 — Ocean-Dwelling Intelligences 13:00 — Illegal Shadow Operations 17:44 — Suspect Scientist Assassinations 24:13 — Directed Energy Weapons 28:47 — Military Industrial Complex 37:33 — Global Defense Murders 41:41 — Spacetime Physics Theories 47:29 — Quantum Entanglement Mechanics 49:38 — CIA Remote Viewing 58:02 — Stock Market Exploits 01:01:58 — Managing Public Panic 01:21:20 — Physical Intelligence Implants 01:40:16 — Real Mandela Effects Shopify: Launch your dream business with Shopify. Sign up for your $1/month trial at https://Shopify.com/Jillian and start selling today! Superpower: Stop guessing about your health—get $20 off Superpower at https://superpower.com/JILLIAN with code JILLIAN Learn more about your ad choices. Visit megaphone.fm/adchoices

David Grusch served 14 years in the Air Force, reaching Major, including a combat tour in Afghanistan. Grusch also held senior intelligence roles at the National Geospatial-Intelligence Agency and the National Reconnaissance Office and represented the latter on the Unidentified Aerial Phenomena (UAP) Task Force from 2019 until 2021. In 2022, he filed a whistleblower complaint deemed “credible and urgent.” In 2023, Grusch testified before Congress, alleging that elements of the U.S. government had thwarted Congressional oversight, withheld information from proper Executive Branch officials, and illegally concealed programs tied to the recovery and reverse engineering of craft of unknown, non-human origin. SUPPORT OUR WORK https://www.judicialwatch.org/donate/thank-youtube/ VISIT OUR WEBSITE http://www.judicialwatch.org

Join Dr. Isabelle Amigues as she introduces Dr. Susanna Chatterjee-Morris, an expert in both gynecology and obstetrics. They will discuss important topics concerning women's health and reproductive health. This discussion offers valuable insights into female health within the broader healthcare landscape.Why are women with autoimmune diseases more likely to feel dismissed or “gaslit” in healthcare?Is it safe to continue biologics during pregnancy?Can inflammation impact ovarian reserve and fertility?What role do hormones play in autoimmune flares during perimenopause and menopause?This episode explores:• Rheumatoid arthritis and pregnancy management• Fertility preservation (egg vs. embryo freezing)• Biologics vs. methotrexate in reproductive years• GLP-1 medications and unexpected pregnancy• Postpartum autoimmune flares• Inflammation and infertility• Why pregnant patients are often undertreated• Hormone balance and autoimmune prognosisIf you are navigating autoimmune disease, trying to conceive, pregnant, postpartum, or entering perimenopause, this conversation is essential.Women's health deserves better research, better collaboration between specialties, and better advocacy.

The Immune team talks all about cytokines, from what they are to immunotherapies against them to treat diseases. Hosts: Vincent Racaniello, Cindy Leifer, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Non-specific virus neutralization by IgM and complement (mBio 2026) Natural antibodies against viruses (Virology blog, 2009) Biologics against inflammatory cytokines (Int J Cell Bio, 2016) Biologics against allergic cytokines (JACI, 2022) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

On this episode of Somewhere in the Skies LIVE, Ryan & Suzanne break down the latest news, including: Has a second Sphinx been discovered at Pyramids of Giza? NASA Artemis launches to the Moon on April 1st. Is NASA really building a permanent base on the Moon? Scientists suggest the best exoplanet candidates for with alien life. Have the groundbreaking papers by Dr. Beatriz Villarreol finally been validated? Japan's landmark proposal to establish a UAP office. David Grusch is suing the Department of Defense. The Mark Christopher Lee/Bigelow story gets worse. A new documentary to follow the life and work of Jeremy Corbell. Scientist steals biological materials from location connected to Varginha alien case. The Bill Maher segment on UFOs has people talking. Please take a moment to rate and review us on Spotify and Apple. Follow Suzanne on X: https://x.com/csuzannelanders Book Ryan on CAMEO at: https://www.cameo.com/ryansprague51?utm_campaign=profile_share Patreon: http://www.patreon.com/somewhereskies ByMeACoffee: http://www.buymeacoffee.com/UFxzyzHOaQ PayPal: sprague51@hotmail.com Substack: https://ryansprague.substack.com/ All Socials and Books: https://linktr.ee/somewhereskiespod Email: ryan.sprague51@gmail.com SpectreVision Radio: https://www.spectrevision.com/podcasts Opening Theme Song by Septembryo Closing Song by Per Kiilstofte Copyright © 2026 Ryan Sprague. All rights reserved. Livestream Music by ‘Punch Deck' - Listen and Subscribe at: http://www.youtube.com/watch?v=vFC8L5srkt4 #UFOs #UFOnews #SpaceNews #NASA #NASAArtemis #UAP #Alien #Aliens #DavidGrusch #JeremyCorbell #Unexplained #Egypt #AncientEgypt Learn more about your ad choices. Visit megaphone.fm/adchoices

Full Show Notes: https://bengreenfieldlife.com/lavalle/ In this episode, I sit down with the legendary clinical pharmacist Jim LaValle for a fascinating exploration of some of the most innovative approaches to health, performance, and longevity. We discuss everything from peptides and small molecules for mitochondrial and kidney support to the science behind improving VO2 max, brain function, sleep, and more. Jim LaValle unpacks his decades of experience, shares cutting-edge research on metabolic health, and explains the power of his Metabolic Code test—which I recently tried myself—for identifying and addressing the biggest bottlenecks in your health journey. Throughout our conversation, we swap stories about nutrition missteps (think gallons of dairy and endless antibiotics), dive into the practical application of peptides like KPV, BPC-157, and lorazotide for healing the gut, and examine trends Jim repeatedly sees even in high performers—like stress-driven hormone changes and sneaky signs of inflammation. If you’re curious about how personalized lab testing, wearable data, and smart supplementation can help you feel better, perform better, and age powerfully, you’ll love the insights in this episode. James "Jim" B. LaValle, B.S.Pharm, CCN, MT, DHM, DHPh, is an internationally recognized clinical pharmacist, author, and board-certified clinical nutritionist, with over 40 years of clinical experience in natural products, lifestyle, drug/nutrient depletion, compounding pharmacy, and peptides. Episode Sponsors: Truvaga: Balance your nervous system naturally with Truvaga's vagus nerve stimulator. Visit Truvaga.com/Greenfield and use code GREENFIELD30 to save $30 off any Truvaga device. Calm your mind, focus better, and recover faster in just two minutes. ZBiotics Pre-Alcohol Probiotic: The world's first genetically engineered probiotic that helps break down the toxic byproduct of alcohol, Zbiotics Pre-Alcohol allows you to enjoy your night out and feel great the next day. Order with the confidence of a 100% money-back guarantee and 15% off your first order at zbiotics.com/BEN15. TRIUMPH Coaching: Join me for one-on-one coaching with me and my hand-picked team, custom-built around your labs, your lifestyle, and goals, until you actually hit them. No guesswork. Just results. If you’re finally ready to stop wasting time and money and start living the boundless life you know is possible, go to jointriumphcoaching.com and book your call. Just Thrive: Take the Just Thrive FEEL BETTER challenge today, and save 20% on your first Gut Essentials Bundle. Just Thrive Probiotic is the only probiotic clinically proven to arrive 100% alive in your gut, reducing bloat, better energy, and even clearing skin. Digestive Bitters packs 12 science-backed herbs in one tasteless capsule that jumpstarts your digestion and supports GLP-1 production so cravings don’t control you. Visit justthrivehealth.com/BEN and save 20% with promo code BEN. See the difference for yourself or get a full product refund, no questions asked. Boundless Bar: If you’re ready to fuel workouts, sharpen your focus, and support whole-body vitality, grab your Boundless Bars now at boundlessbar.com —and save 10% when you sign up for a Boundless Bar subscription.See omnystudio.com/listener for privacy information.